Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2022-09-01 Board/Management Inform…
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext nomme Rob Quinn au poste de Directeur Financier
Board/Management Information Classification · 1% confidence The document is a press release dated September 1, 2022, announcing the appointment of Rob Quinn as the new Chief Financial Officer (Directeur Financier) and noting the departure of the previous CFO. This content directly relates to changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate classification for announcements regarding changes in senior management.
2022-09-01 French
Pharnext Announces a €2.5m Loan Agreement with Néovacs
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 23rd, 2022, announcing that Pharnext has signed a €2.5 million loan agreement with Néovacs. This announcement details a specific financing activity (a loan) and potential future financing agreements. This clearly falls under the category of updates on company fundraising or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is relatively short for a full regulatory report, and it is an announcement of a specific financial event, not a general report publication announcement (RPA).
2022-08-23 English
Pharnext annonce un accord de prêt avec Néovacs pour un montant de 2,5 millions d’euros
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 23, 2022, announcing that Pharnext has signed a loan agreement ('accord de prêt') with Néovacs for 2.5 million euros. This announcement details a specific financing activity, including terms (interest rate, duration) and potential future broader financing agreements. This clearly falls under the category of updates on company fundraising or financing activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific corporate action announcement.
2022-08-23 French
Pharnext nomme Antoine Gravelle au poste de Directeur Juridique
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of Antoine Gravelle as the new Chief Legal Officer (Directeur Juridique) of Pharnext, effective July 1, 2022. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns specific personnel changes.
2022-07-05 French
Pharnext Appoints Antoine Gravelle as General Counsel
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new General Counsel (Antoine Gravelle) and includes commentary from the CEO. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of Board/Management Information.
2022-07-05 English
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
Regulatory Filings Classification · 1% confidence The document is a press release from Pharnext SA dated June 28th, 2022, announcing that findings from their 'CMT&Me' study will be presented at the International Congress on Neuromuscular Disease (ICNMD) 2022. It details the titles of the poster presentations and the conference schedule. This is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement about scientific data presentation, which falls under general corporate communication regarding research progress. Since there is no specific category for 'Scientific Presentation Announcement,' and it is a formal announcement of company activity, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, although 'Investor Presentation' (IP) is related to investor communication, this is specifically about a scientific congress presentation, making RNS the most appropriate fallback for a non-standard announcement.
2022-06-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.